Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 27;14(3):596–608. doi: 10.1080/21645515.2017.1384106

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published with license by Taylor & Francis

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Disposition of participants in the study. 2225 participants were included and randomized 2:2:2:1:1 to receive a single dose of one of the three lots of the 2014–2015 formulation of IIV4, IIV3-1, or IIV3-2. IIV4 contained the A(H1N1), A(H3N2), B Victoria lineage, and B Yamagata lineage strains; IIV3-1 contained the two A strains and the B Victoria lineage strain (IIV3-1); IIV3-2 was the 2014–2015 licensed IIV3 and contained the two A strains and the B Yamagata lineage strain. All but three participants were vaccinated. Reasons for discontinuation included a severe adverse event (SAE), voluntary withdrawal not for an adverse event (AE), noncompliance with the study procedures, and loss to follow-up (LFU). The high number of protocol violations in the IIV3-1 group after day 21 and before month 6 was due to 47 participants who were offered and accepted to receive a second vaccination with the commercial vaccine (IIV3-2) so that they would be covered for the B/Yamagata-lineage strain.